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STATEMENT OF THE PROBLEM
Background
Aging Baby-boomer Population
 Aspirin use increases with age.13 The aging baby-boomer population is resulting in more patients who are not able to 
take medication orally (NPO).
 Rectal suppositories are the commonly used alternative for NPO patients. 
Current Aspirin Suppositories
 Only one is available from Paddock labs. Previous research does not specify if this was the formulation used.
 Very little research is available concerning aspirin suppositories.
 Current research is dated and more foundational in nature rather than comprehensive and adequately powered
 A study concluded that rectal absorption of aspirin was slow and long in duration whereas a study by Broom 
stated that serum levels were short-lived.1
 The most foundational were a series of studies from the seventies that involved very small sample sizes and were 
inadequately powered.8,14,3
Mechanism of Action6
•Aspirin is hydrolyzed to the active component salicylate by esterases in the GI mucosa, red blood cells, synovial fluid, 
and blood
•Aspirin irreversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes via acetylation.
•This causes a decrease in the formation of prostaglandin precursors and irreversibly inhibits the formation of 
thromboxane A2, thus inhibiting platelet aggregation.
•This action also has antipyretic, analgesic, and anti-inflammatory benefit.
Significance of the Problem
 The demand for dosage forms that accommodate patients who can take nothing by mouth 
 The absorption of the current aspirin suppository available is poor and erratic
 There is  a need for a better aspirin suppository product to enhance absorption and therapeutic effect.
To create a novel aspirin suppository with increased absorption of cells.
OBJECTIVES
All data will be expressed as mean±standard deviation and will be analyzed using repeated measures 
ANOVA with Dunnett’s post-test, as appropriate (SPSS version).  A value of P, 0.05 (two-tailed) is 
considered statistically significant.
PROPOSED ANALAYSES
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PROPOSED METHODS
Study Design:
• Prospective, pre-clinical in-vitro study to detect aspirin (in suppository formulation) absorption 
through rectal cells
Sample:
 Cultured HT-29 colonic adenocarcinoma cell line 
 Cultured CaCo2 colorectal adenocarcinoma cell line
 Selected cell-line will be cultured for use in the developed assay to test the absorption of aspirin 
formulated with different bases and excipients
Data Collection:
Phase One: Comparison of commercial aspirin suppository absorption through HT-29 versus CaCo-2 
cell cultures.
• Cultured cells in the assay will be seeded to monolayer filter inserts to approximate rectal cells and 
be the barrier which the aspirin must cross.
• Aspirin that crosses the barrier of the cells will be determined by an absorption reading by the 
Promega GloMax Multi-Plate reader. 15 This reading will be a measurement of the amount of COX-
1 acetylation.
Phase Two: Comparison of aspirin bases and excipients using the preferred cell line.
• Cultured cells (from the preferred cell line) will be cultured and used in the developed assay.2
• Aspirin in addition to the chosen bases/excipients will be run through the assay.
• Serum containing the cellular components of the cell line will be placed in well plates and 
absorption (measurement of COX-1 acetylation in the cells) will be determined by the Promega
GloMax. This will be our primary way of measuring the amount of aspirin absorbed.
Measurement:
• The Promega GloMax Multi-Plate reader will be used to generate a standard curve of aspirin 
absorption using intracellular aspirin concentration (measured by the amount of acetylation of 
COX-1).
• These absorption curves will be created for each "formula" of aspirin and will be compared to 
each other and to the curve from the commercially available aspirin suppository formulation.
PROJECT TIMELINE
 The assay may not fully approximate the actual cells in the rectum.
 We do not know the demand for aspirin suppositories.
 Sensitivity measurements in the assay of acetyl salicylic absorption. 
 Unable to use radioactive tagging or isotopes.
LIMITATIONS
Dates Expectation
August-December 2013 Research proposal development
January-May 2014 Obtain the assay, reagents, and aspirin
August-December 2014 Assay validation
January-May 2015 Test and evaluate aspirin suppository formulations
August-December 2015 Propose human studies
January-May 2016 Conduct study
• A follow up clinical trial will be conducted to compare the efficacy of the novel suppository formulation 
against the leading formulation for both pain management and cardiac regimens. 
• Efficacy of oral versus rectal routes for aspirin can be evaluated with the best absorbed formulations.
• Need assessment research will be conducted to identify which health care settings would benefit most 
from an improved aspirin suppository formulation.
FUTURE DIRECTIONS
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Assay 
Development
•Culturing HT-29 and
Caco-2 cells
•Determining the 
most efficient cell line
Transport 
Study
•Running the different  
formulations of aspirin 
through the assay
•Extracting the cell   
components and analyzing 
COX-1 inhibition
Absorption 
Analysis
•Promega GloMax
•Creation of an 
absorption curve
ALTERNATIVE HYPOTHESIS
• The inclusion of zinc and carnosine excipients and selected bases in the formulation of aspirin (or sodium salicylate) 
suppositories increases the absorption in HT-29 colonic adenocarcinoma cells or Caco-2 cell lines.
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